- Home
- ESS vs BIIB Comparison
ESS vs BIIB Comparison
Compare ESS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESS
- BIIB
- Stock Information
- Founded
- ESS 1971
- BIIB 1978
- Country
- ESS United States
- BIIB United States
- Employees
- ESS N/A
- BIIB N/A
- Industry
- ESS Real Estate Investment Trusts
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ESS Real Estate
- BIIB Health Care
- Exchange
- ESS Nasdaq
- BIIB Nasdaq
- Market Cap
- ESS 17.9B
- BIIB 18.8B
- IPO Year
- ESS 1994
- BIIB 1991
- Fundamental
- Price
- ESS $283.91
- BIIB $131.20
- Analyst Decision
- ESS Hold
- BIIB Buy
- Analyst Count
- ESS 19
- BIIB 26
- Target Price
- ESS $310.41
- BIIB $194.95
- AVG Volume (30 Days)
- ESS 425.8K
- BIIB 1.7M
- Earning Date
- ESS 04-29-2025
- BIIB 05-01-2025
- Dividend Yield
- ESS 3.62%
- BIIB N/A
- EPS Growth
- ESS 27.78
- BIIB 26.39
- EPS
- ESS 10.45
- BIIB 10.12
- Revenue
- ESS $1,861,154,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- ESS $4.13
- BIIB N/A
- Revenue Next Year
- ESS $3.95
- BIIB N/A
- P/E Ratio
- ESS $27.16
- BIIB $12.83
- Revenue Growth
- ESS 9.74
- BIIB 1.59
- 52 Week Low
- ESS $243.85
- BIIB $110.04
- 52 Week High
- ESS $317.73
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- ESS 52.68
- BIIB 59.82
- Support Level
- ESS $269.10
- BIIB $123.97
- Resistance Level
- ESS $289.12
- BIIB $132.94
- Average True Range (ATR)
- ESS 5.82
- BIIB 3.49
- MACD
- ESS 0.02
- BIIB 1.04
- Stochastic Oscillator
- ESS 73.95
- BIIB 88.37
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 256 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.